Pneumococcal Disease: Global Disease Prevention Strategies with a Focus on the Challenges in Iraq
- PMID: 37275330
- PMCID: PMC10237204
- DOI: 10.2147/IJGM.S409476
Pneumococcal Disease: Global Disease Prevention Strategies with a Focus on the Challenges in Iraq
Abstract
Pneumococcal disease is a global public health concern that significantly contributes to clinical disease burden and economic burden. Patients frequently afflicted are young children and older adults, as well as the immunocompromised population. Immunization is the most effective public health strategy to combat pneumococcal disease and several vaccine formulations have been developed in this regard. Although vaccines have had a significant global impact in reducing pneumococcal disease, there are several barriers to its success in Iraq. The war and conflict situation, increasing economic crises and poverty, poor vaccine accessibility in the public sector, and high vaccine costs are a few of the major obstacles that impede a successful immunization program. The last reported third dose pneumococcal conjugate vaccine coverage for Iraq was 37% in 2019, which is expected to reduce even further owing to the COVID-19 pandemic. Thus, strategies and policies to improve pneumococcal vaccine availability and coverage need to be strengthened to achieve maximum benefits of immunization. In the current review, we provide an overview of the existing knowledge on pneumococcal disease-prevention strategies across the globe. The main aim of this manuscript is to discuss the current status and challenges of pneumococcal vaccination in Iraq as well as the strategies to prevent pneumococcal infections.
Keywords: Iraq; Streptococcus pneumoniae; pneumococcal disease; pneumococcal disease-prevention strategies; pneumococcal pneumonia; pneumococcal vaccines.
© 2023 Al-Jumaili et al.
Conflict of interest statement
Delan Ikram and Ali Al-Jabban are Pfizer employees. The authors report no other conflicts of interest in this work.
Figures
Similar articles
-
20-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults.Drugs. 2022 Jun;82(9):989-999. doi: 10.1007/s40265-022-01733-z. Epub 2022 Jul 6. Drugs. 2022. PMID: 35793027 Review.
-
Pneumococcal conjugate vaccine for young children.Manag Care. 2000 Sep;9(9):49-52, 54, 56-7 passim. Manag Care. 2000. PMID: 11116663 Review.
-
Recent advances in the epidemiology and prevention of Streptococcus pneumoniae infections.F1000Res. 2020 May 7;9:F1000 Faculty Rev-338. doi: 10.12688/f1000research.22341.1. eCollection 2020. F1000Res. 2020. PMID: 32411353 Free PMC article. Review.
-
Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.Vaccine. 2015 May 7;33 Suppl 1:A209-18. doi: 10.1016/j.vaccine.2014.12.043. Vaccine. 2015. PMID: 25919163
-
Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.Clin Microbiol Infect. 2013 Oct;19 Suppl 1:1-9. doi: 10.1111/1469-0691.12320. Clin Microbiol Infect. 2013. PMID: 24083785 Review.
Cited by
-
Implications of Cross-Reactivity and Cross-Protection for Pneumococcal Vaccine Development.Vaccines (Basel). 2024 Aug 28;12(9):974. doi: 10.3390/vaccines12090974. Vaccines (Basel). 2024. PMID: 39340006 Free PMC article. Review.
-
Novel manufacturing process of pneumococcal capsular polysaccharides using advanced sterilization methods.Front Bioeng Biotechnol. 2024 Aug 7;12:1451881. doi: 10.3389/fbioe.2024.1451881. eCollection 2024. Front Bioeng Biotechnol. 2024. PMID: 39170064 Free PMC article.
-
Subtractive genomics and drug repurposing strategies for targeting Streptococcus pneumoniae: insights from molecular docking and dynamics simulations.Front Microbiol. 2025 Mar 18;16:1534659. doi: 10.3389/fmicb.2025.1534659. eCollection 2025. Front Microbiol. 2025. PMID: 40170924 Free PMC article.
References
-
- Centers for Disease Control and Prevention. Manual for the surveillance of vaccine-preventable diseases. Available from: https://www.cdc.gov/vaccines/pubs/surv-manual/chpt11-pneumo.html. Accessed May 18, 2023.
-
- World Health Organization. Pneumococcal Disease. Available from: https://www.who.int/teams/health-product-policy-and-standards/standards-.... Accessed March 1, 2022.
-
- Centers for Disease Control and Prevention. Pneumococcal disease: global pneumococcal disease and vaccination. Available from: https://www.cdc.gov/pneumococcal/global.html. Accessed May 18, 2023.
-
- Wahl B, O’Brien KL, Greenbaum A, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15. Lancet Glob Health. 2018;6(7):e744–e757. doi:10.1016/S2214-109X(18)30247-X - DOI - PMC - PubMed
-
- VIEW-hub. International Vaccine Access Center [IVAC], Johns Hopkins Bloomberg school of public health. Available from: https://view-hub.org/. Accessed May 18, 2023.
Publication types
LinkOut - more resources
Full Text Sources